Pemro 100 MG (Nivolumab)
Product Name : Pemro
Generic Name : Nivolumab
Formulation : Injection
Available Pack Size : 1’s
Available Strengths : 100 mg
Registrations : Bangladesh
Product Information
Pemro (Pembrolizumab) 100mg/4mL is a humanised monoclonal antibody and immune checkpoint inhibitor used across one of the broadest ranges of approved cancer indications of any oncology biologic, including melanoma, non-small cell lung cancer, and several other solid tumours and lymphomas. It works by blocking the PD-1 (programmed death receptor-1) pathway on T cells, releasing a natural brake on the immune system so that a patient’s own T cells can recognise and attack cancer cells more effectively. Pemro is administered as an intravenous infusion by a qualified healthcare professional and must never be self-administered. Manufactured by Beacon Pharmaceuticals PLC, Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Pemro (Pembrolizumab) 100mg
| Brand Name | Pemro (Pembrolizumab) |
| Generic Name | Pembrolizumab (Humanised IgG4 Kappa Monoclonal Antibody) |
| Drug Class | PD-1 Immune Checkpoint Inhibitor |
| Strength | 100mg/4mL (25mg/mL) Concentrate for IV Infusion |
| Formulation | Single-Use Vial for Intravenous Infusion (Clinician-Administered) |
| Pack Size | 1 Single-Use Vial |
| Primary Indication | Multiple Solid Tumours and Lymphomas, Including Melanoma, NSCLC, and Tumour-Agnostic (MSI-H/TMB-H) Indications |
| Regulatory Approvals | USFDA Approved (Multiple Cancer Indications). EMA Approved. |
| Originator Brand | Keytruda by Merck (MSD) |
| Manufacturer | Beacon Pharmaceuticals PLC, Mymensingh, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration | Registered in Bangladesh |
| Storage Conditions | Refrigerate at 2 to 8 degrees Celsius. Do not freeze. Protect the vial from light. Cold-chain handling and transport is required for this product. |
How Pemro (Pembrolizumab) Works
Pemro contains Pembrolizumab, a humanised monoclonal antibody produced in recombinant Chinese hamster ovary (CHO) cells, engineered to block the Programmed Death receptor-1 (PD-1) pathway. PD-1 is a receptor found on the surface of activated T cells that normally acts as an immune “off switch.” Many tumours exploit this pathway, expressing PD-L1 and PD-L2 ligands that bind PD-1 and suppress the T-cell response, allowing cancer cells to evade immune attack.
By binding to the PD-1 receptor, Pembrolizumab blocks its interaction with PD-L1 and PD-L2, releasing this immune checkpoint and restoring the ability of a patient’s own T cells to recognise and destroy cancer cells. This mechanism, known as immune checkpoint inhibition, is fundamentally different from chemotherapy or targeted kinase inhibitors, since Pemro does not act directly on the tumour but instead reactivates the body’s own anti-tumour immune response.
Pemro is given as a slow intravenous infusion by a qualified oncology healthcare team, typically every 3 or every 6 weeks depending on the regimen selected, and is used both as monotherapy and in combination with chemotherapy or other targeted agents across a wide range of approved cancer types.
Indications for Pemro (Pembrolizumab)
Pemro (Pembrolizumab) has one of the broadest ranges of approved indications of any cancer immunotherapy, including the following:
|
Melanoma and Non-Small Cell Lung Cancer For unresectable or metastatic melanoma, including adjuvant use after resection, and for NSCLC in first-line, combination, adjuvant, and neoadjuvant settings. |
Head and Neck, Lymphoma, and Urothelial Cancers For head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and urothelial (bladder) cancer. |
|
Additional Solid Tumours Including gastric, oesophageal, cervical, hepatocellular, renal, endometrial, biliary tract, and triple-negative breast cancer, in specific settings and lines of therapy. |
Tumour-Agnostic Indications (MSI-H / TMB-H) For unresectable or metastatic microsatellite instability-high (MSI-H), mismatch repair deficient (dMMR), or tumour mutational burden-high (TMB-H) solid tumours, regardless of where the cancer originated in the body, after prior treatment where appropriate. |
The specific indication, dose, treatment line, and any combination therapy must be confirmed by the treating oncologist, as eligibility criteria and biomarker requirements vary by cancer type.
Benefits of Pemro (Pembrolizumab) 100mg
|
Broadest Immunotherapy Indication Range Pemro is approved across more cancer types and treatment settings than almost any other single oncology biologic, reflecting more than a decade of accumulated clinical evidence. |
Tumour-Agnostic Precision Option For MSI-H, dMMR, or TMB-H tumours, Pemro can be used based on a tumour’s genetic profile rather than where in the body it originated. |
Flexible Dosing Schedules Pemro can be dosed every 3 weeks or every 6 weeks in most adult settings, allowing the treatment schedule to be tailored to the patient and clinic. |
|
Affordable Alternative to Keytruda Pemro contains the same active ingredient as Keytruda by Merck, at a significantly lower cost, making immune checkpoint inhibitor therapy more financially accessible. |
Combination-Ready Pemro is used both as monotherapy and in combination with chemotherapy or other targeted agents, giving oncologists flexibility across many treatment lines. |
cGMP Certified Manufacturing Produced by Beacon Pharmaceuticals PLC under cGMP-compliant biologics manufacturing standards, with cold-chain handling maintained throughout distribution. |
How Pemro (Pembrolizumab) Is Administered
Route: Intravenous infusion only. Pemro must be diluted before use and administered by a qualified healthcare professional in a clinical setting. It must never be self-administered, and must never be given as an intravenous push or bolus injection.
Standard adult dosing: 200mg (two 100mg vials) every 3 weeks, or 400mg (four 100mg vials) every 6 weeks, infused over approximately 30 minutes. The specific dose, schedule, and any companion chemotherapy or targeted agent will be determined by the treating oncologist based on the cancer type and treatment line.
Treatment duration: Treatment is generally continued until disease progression, unacceptable toxicity, or, in some indications, for a defined maximum duration (such as up to 2 years), as directed by the prescribing oncologist.
Renal or hepatic impairment: No dose adjustment is generally required for mild to moderate renal or hepatic impairment; use with caution as directed by the treating oncologist.
Paediatric use: Approved for certain paediatric indications, such as classical Hodgkin lymphoma and specific tumour-agnostic uses, at weight-based doses determined by a paediatric oncology specialist.
Monitoring During Treatment
Regular monitoring is essential throughout Pemro treatment. Your oncology team will monitor for signs of immune-mediated inflammation in the lungs, bowel, liver, kidneys, skin, and endocrine glands at each visit, along with periodic liver function tests, thyroid function tests, and blood glucose. Monitoring also includes close observation during and immediately after each infusion for signs of an infusion-related reaction. Report any new or worsening cough, breathlessness, diarrhoea, abdominal pain, yellowing of the skin or eyes, unusual fatigue, muscle weakness, severe rash, or signs of hormonal imbalance (such as excessive thirst, weight change, or mood changes) to your oncology team immediately, even weeks or months after your last dose.
Drug Interactions and Important Information
Use of systemic corticosteroids or other immunosuppressants before starting Pemro, other than to manage an immune-mediated adverse reaction or for a condition unrelated to cancer, may reduce its effectiveness and should be discussed with your oncologist. Pemro used before or after allogeneic haematopoietic stem cell transplantation has been associated with an increased risk of transplant-related complications, including graft-versus-host disease.
Avoid live vaccines during treatment with Pemro. Women of childbearing potential should use effective contraception during treatment and for at least 4 months after the final dose. Always inform your oncology team of all medications, supplements, and herbal products you are currently taking before starting Pemro.
Side Effects and Precautions
|
Common Side Effects Fatigue Swelling of the ankles, feet, or hands Itchy skin and rash Nausea, vomiting, and abdominal pain Decreased appetite and diarrhoea Fever and cough Constipation or trouble sleeping |
Serious Warnings and Precautions Immune-mediated pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies (thyroid, adrenal, pituitary, type 1 diabetes). Severe skin reactions, including rare Stevens-Johnson syndrome and toxic epidermal necrolysis. Infusion-related reactions, ranging from mild to severe. Complications of allogeneic stem cell transplantation when used before or after transplant. Embryo-foetal toxicity. Not recommended during pregnancy or breastfeeding. |
Who Should Use Pemro (Pembrolizumab)?
Pemro is suitable for adult and, in some indications, paediatric patients with an approved cancer diagnosis matching one of Pemro’s authorised indications, such as melanoma, NSCLC, head and neck cancer, Hodgkin lymphoma, urothelial cancer, or an MSI-H/TMB-H tumour confirmed by an approved biomarker test. It is prescribed and administered exclusively by medical oncologists and their clinical teams in a hospital or infusion centre setting. A thorough medical assessment including baseline organ function, biomarker testing where relevant, and a review of autoimmune disease history is required before initiating treatment.
Manufacturer: Beacon Pharmaceuticals PLC
Beacon Pharmaceuticals PLC is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh, and the number one oncology and specialty medicine company in the country. Beacon is the first company in Bangladesh to export cancer drugs and currently exports to Asia, Africa, Europe, and Latin America, with a growing biologics manufacturing capability supporting complex monoclonal antibody products such as Pemro. Beacon operates under strict WHO-GMP, cGMP, and ISO-certified standards, offering an affordable alternative to Keytruda by Merck at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Pemro (Pembrolizumab) is accessible to hospitals, infusion centres, and healthcare providers worldwide through reliable, temperature-controlled worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Pemro (Pembrolizumab) from Mediaid Pharmacy?
Pemro represents one of the most established and broadly indicated immune checkpoint inhibitors in oncology. As the generic equivalent of Keytruda by Merck, it delivers the same active ingredient, Pembrolizumab, with the same proven PD-1 blocking mechanism at a dramatically more affordable price. Manufactured by Beacon Pharmaceuticals PLC under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy with cold-chain logistics, Pemro gives hospitals and infusion centres worldwide access to advanced cancer immunotherapy without the financial burden of brand-name alternatives. For healthcare providers seeking a proven, affordable, and accessible Pembrolizumab option with worldwide delivery, Pemro from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Pemro (Pembrolizumab)
What is Pemro (Pembrolizumab) used for?
Pemro (Pembrolizumab) is an immune checkpoint inhibitor used across a very wide range of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, urothelial cancer, and MSI-H/TMB-H tumour-agnostic indications. It works by blocking the PD-1 pathway, allowing the patient’s own immune system to attack cancer cells more effectively.
How is Pemro (Pembrolizumab) given?
Pemro is given only as a slow intravenous infusion by a qualified oncology healthcare team in a hospital or infusion centre, typically over about 30 minutes, once every 3 weeks or once every 6 weeks depending on the regimen. It must never be self-administered at home.
What strength is Pemro available in?
Pemro is supplied as a 100mg/4mL (25mg/mL) single-use vial. Depending on the prescribed dose, one infusion may require multiple vials, for example two vials for a 200mg dose or four vials for a 400mg dose.
Is Pemro the same as Keytruda (Pembrolizumab by Merck)?
Yes. Pemro is the generic equivalent of Keytruda. Both contain the same active ingredient, Pembrolizumab, and work through the same PD-1 blocking mechanism. Pemro is manufactured by Beacon Pharmaceuticals PLC in Bangladesh and offers the same clinical mechanism as Keytruda at a significantly lower cost.
What are the side effects of Pemro (Pembrolizumab)?
Common side effects include fatigue, swelling, itching, nausea, and decreased appetite. Serious but less common risks include immune-mediated inflammation of the lungs, bowel, liver, kidneys, skin, or endocrine glands, which can occur at any time during or after treatment. Always consult your oncology team for a complete assessment of your individual risks and benefits before starting treatment.
Can Pemro be used with other medications?
Systemic corticosteroids or other immunosuppressants taken before starting Pemro may reduce its effectiveness unless used to manage a side effect. Live vaccines should be avoided during treatment. Always inform your oncology team of all medications, supplements, and herbal products you are taking before starting Pemro.
Is Pemro (Pembrolizumab) safe during pregnancy or breastfeeding?
No. Pemro is not recommended during pregnancy or breastfeeding, as it can cause foetal harm. Women of childbearing potential should use effective contraception during treatment and for at least 4 months after the final dose. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Pemro (Pembrolizumab) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Pemro (Pembrolizumab) 100mg globally with cold-chain worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Pemro (Pembrolizumab) 100mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
